Physician profile
Michael John Baker
NPI 1891354114
$3,592.51
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,449 · 2022: $1,337 · 2023: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.21 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.54 | 2021-2023 | |
| Lundbeck LLC | $470.00 | 2021-2023 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $449.84 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.25 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $278.57 | 2021-2023 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $197.37 | 2021-2023 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $190.07 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $137.48 | 2021-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $97.70 | 2021 | |
| Alkermes, INC. | $91.70 | 2021-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $77.00 | 2022-2023 | Auvelity |
| Eisai INC. | $76.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $62.66 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $44.90 | 2022 | |
| Idorsia Pharmaceuticals US INC | $39.99 | 2022-2023 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $33.68 | 2022 | |
| Tris Pharma INC | $27.27 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $21.93 | 2022 | |
| Bausch Health US, LLC | $15.50 | 2022 | |
| Noven Therapeutics, LLC | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.